Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of KPC000154 in Healthy Adult Volunteers
NCT06867406Phase 1Not yet recruiting
- Start
- Mar 2025
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of KPC000154 in Nonalcoholic steatohepatitis (NASH) (12 arms). Primary endpoints: Maximum Plasma Concentration at 12.8 month, Area Under the Plasma Concentration-Time Curve from Time Zero to Time t at 12.8 month and 1 more. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
KPC000154
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT06867406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06867406.